Karl Congratulations Well deserved

Austin Hospital Transplant Team from Australia visiting UHB to observe our transplant services and mutual learning University Hospitals Birmingham

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease | New England Journal of Medicine nejm.org/doi/full/10.10… UHB Research

Great talk by Rakesh Popat

With 2 legends

Congratulations to John Gribben for receiving the Josep Carreras award at #EHA2024

Congratulations to our Upper Fifth pupils who have achieved unprecedented GCSE results!🎉 Key highlights include: ⭐️60% of grades were 9s ⭐️84% of grades were 9-8s ⭐️95% of grades were 9-7s Read more about today's results➡kehs.org.uk/news/unprecede…

Approach to pancytopenia: From blood tests to the bedside sciencedirect.com/science/articl…

Amazing news and well deserved Nick Duncan !! Congratulations 🥳

Final thoughts of the day from Anjali Zarkar, lead of the renal #SABR subgroup: can we set up a national registry? Is there a trial we can recruit into? SABR The Royal College of Radiologists

Large retrospec fludara vs benda in CAR LD therapy • almost 450 benda pts • benda: ⬇️ORR, ⬇️CRR, ➡️ PFS, OS • benda had less CRS / ICANs / cytopenia • NB more tisacel with benda Interesting. Safety better with benda but seems to be some reduction in efficacy. #ASH24 #lymsm

Opportunity for UK group for prospective data collection even though our use of Benda LD is limited ? Benda LD for expected higher ICANS or CRS

Great Ham-Wasserman lecture today @ASH24

Grateful to all our CNS for their dedication to patient care and looking after the team UHB Cancer Services #CNS day

Great news - NICE have approved AVD-BV for 1L treatment of advanced stage Hodgkin Lymphoma. Great to have an additional option for these patients. #lymsm nice.org.uk/news/articles/…

CPR in birds! Amazing to see

22nd Post ASH meeting started with WMRC update #wmrc #post ASH

➡️➡️Big CLL news! Munir et al OS and PFS adv for MRD driven I&V over ibrutinib in 1L #CLL #EHA2025 Congrats to all FLAIR trial 🇬🇧group Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia | New England Journal of Medicine nejm.org/doi/full/10.10…

Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia | NEJM nejm.org/doi/full/10.10… Great work from UK Team! Undetectable MRD and extended progression-free survival were more common with ibrutinib–venetoclax than with ibrutinib alone

Another great choice for our patients